focus -WSS

focus

author：entertainment 2025-08-20 09:39:53 - browse：6885

Brain cancer — Michelle Monje/Stanford University/NIH

Tocagen (TOCA) said Tuesday that a Phase 3 clinical trial involving a novel gene therapy for aggressive brain tumors will continue to a final analysis later this year, following an interim look at patient survival data conducted by independent monitors. Tocagen’s stock price dropped sharply.

The San Diego-based biotech pitched the study’s continuation as an encouraging sign for its gene therapy called Toca 511/Toca FC, which is designed to deliver a localized chemotherapy directly to the site of brain tumors.

“We believe the longer-term follow-up of patients in the final analysis, particularly for those randomized in the second enrollment period, will be important in assessing both primary and secondary endpoints,” said Tocagen CEO Marty Duvall, in a statement.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： FDA seeking to stop procedures at two unregulated stem cell clinics

WSS

The PBM ad wars are taking over Washington, D.C.

Trump seeks lengthy delay of classified docs trial, citing upcoming election

UPS workers' union leader explains what's at stake as strike edges closer

Ford plant in Missouri shuts down over 'possible threat,' sheriff's office says

Sen. Bill Cassidy on how to lower drug prices

UPS workers' union leader explains what's at stake as strike edges closer

hotspot

focus

leisure time

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Zelenskyy on how Russian invasion may end, gratitude for US aid and Putin's weakness

Virginia high school admissions case could be legal follow

Masked men burn a market in a Mexican city plagued by gang violence, killing 9 people

DIEP, the 'gold standard' of breast reconstruction, is under threat

Tennessee woman gets emergency hysterectomy after doctors deny early abortion care

In age of alternative facts, a scholarly course on calling out crap

The PBM ad wars are taking over Washington, D.C.

What does generative AI mean for health care? We asked experts

Search resumes for 2 missing children washed away with mom in deadly Pennsylvania flash flood

hotspot

15 die by electrocution after transformer explodes in northern India

Why you get paid to donate plasma but not blood

Vivek Ramaswamy, who's embraced Trump on the campaign trail, condemned him after Jan. 6

A Theranos scientist

The PBM ad wars are taking over Washington, D.C.

Biden administration sends mixed signals on US soldier who crossed into North Korea

knowledge

focus

knowledge

focus